| Literature DB >> 23189167 |
Shabnam Ansari1, Arash Rashidian.
Abstract
OBJECTIVES: We conducted a comparative review of clinical practice guideline development handbooks. We aimed to identify the main guideline development tasks, assign weights to the importance of each task using expert opinions and identify the handbooks that provided a comprehensive coverage of the tasks.Entities:
Mesh:
Year: 2012 PMID: 23189167 PMCID: PMC3506587 DOI: 10.1371/journal.pone.0049864
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Guideline development tasks, their weight scores, and their coverage in the guideline development handbooks.
| Task | Definition | Weight score | No. handbooks mentioning the task (%) |
|
| The process and criteria for selecting and prioritizing topics | 4.5 | 19 (100%) |
|
| A framework that describes the epidemiology of the disease or condition and theaspects of care and the settings is covered by the guideline | 5 | 17 (89.4%) |
|
| Specifying the guideline development project plan including timelinesand project costs | 4 | 12 (63.1%) |
|
| An objective search of important and relevant databases and search enginesfor existing guidelines | 4 | 15 (78.9%) |
|
| Objective appraisal of existing guidelines e.g. byusing AGREE | 4 | 13 (68.4%) |
|
| Describing guideline adaption methods | 4 | 14 (73.6%) |
|
| Contribution of the target population (patients, public, etc.) inrelevant tasks | 4 | 17 (89.4%) |
|
| Describing the composition of guideline development group, includingall relevant stakeholders | 5 | 19 (100%) |
|
| Declaration of guideline development group memberscompeting interests | 4.5 | 14 (73.6%) |
|
| Describing how to run a GDG (meetings, agenda items, chairing,responsibilities and roles) | 5 | 14 (73.6%) |
|
| Developing clinical question according to an objective approach,e.g. PICO framework | 5 | 17 (89.4%) |
|
| Systematic searches of important bibliographicdatabases using sensitive key words | 5 | 15 (78.9%) |
|
| Inclusion and exclusion criteria for selecting theevidence | 4.5 | 17 (89.4%) |
|
| Appraising identified evidences using objective instruments(for example CASP tools) | 5 | 18 (94.7%) |
|
| Describing synthesis approaches of primary studies,including meta-analysis etc. | 5 | 13 (68.4%) |
|
| Describing the process of identifying, selecting andsynthesizing economic evaluation data | 3 | 14 (73.6%) |
|
| Using clear and objective consensus developmenttechniques (e.g. voting, Delphi,…) | 4 | 17 (89.4%) |
|
| Appraising and summarizing the quality and strengthof recommendations | 4 | 18 (94.7%) |
|
| Discussing the approaches used for consideringethical issues in the guideline development process | 4 | 7 (36.8%) |
|
| Interpreting the evidence to make recommendationsand the wording and format of recommendations | 5 | 19 (100%) |
|
| Final consultation with stakeholders beforepublishing the guideline | 4 | 18 (94.7%) |
|
| Describing different publication formats (fullguideline, quick reference guides, information for patient, wed-based publication, …) | 4 | 14 (73.6%) |
|
| Describing how the recommendations can be put intoPractice | 4.5 | 19 (100%) |
|
| Describing a process of pre-testing a guideline in thefield before its final release | 4 | 9 (47.3%) |
|
| The cost and resource implications of implementingthe guideline in practice | 4 | 13 (68.4%) |
|
| Describing monitoring and auditing criteria andindicators to assess guideline implementation | 4 | 14 (73.6%) |
|
| Describes the process, timeline, frequency andcriteria for updating recommendations or correcting errors | 5 | 18 (94.7%) |
Potential additional tasks for guideline development.
|
|
General description of the guideline development handbooks.
| Handbook | Publication year | country of origin | General audience or targeting specific diseases | Website |
| National Institute for Health and Clinical Excellence (NICE) | 2009 | UK | General |
|
| Swiss Centre for International Health (SCIH) | 2011 | Swiss | General |
|
| Scottish Intercollegiate Guidelines Network (SIGN) | 2008 | Scotland | General |
|
| World Health Organization (WHO) | 2012 | International | General |
|
| Canadian Medical Association (CMA) | 2007 | Canada | General |
|
| New Zealand Guidelines Group (NZGG) | 2001 | New Zealand | General |
|
| National Health and Medical Research Council (NHMRC) | 1998 | Australia | General |
|
| American Society of Clinical Oncology (ASCO) | 2011 | USA | Specific |
|
| The Chartered Society of Physiotherapy (CSP) | 2006 | UK | Specific |
|
| International Diabetes Federation (IDF) | 2003 | International | Specific |
|
| Advisory Committee on Health Research (ACHR) | 2006 | International | General |
|
| World Stroke Organization (WSO) | 2009 | International | Specific |
|
| Cancer Care Ontario (CCO) | 2011 | Canada | Specific |
|
| Council of Europe (CE) | 2001 | International | General |
|
| U.S. Preventive Services Task Force (UPSTF) | 2008 | USA | General |
|
| Australian Health Policy Institute (AHPI) | 2008 | Australia | Specific | healthpolicystudies.org.au/ |
| Regional Centre for Quality of Health Care (RCQHC) | 2003 | Regional | Specific |
|
| Royal College of Psychiatrists (RCP) | 1994 | UK | Specific |
|
| World Confederation for Physical Therapy (WCPT) | 2006 | International | Specific |
|
Guideline development handbooks raw and weighted scores.
| Handbook | Raw score | Weighted score | Percentage of maximumweighted score |
|
| 50 | 220 | 93.2 |
|
| 47 | 208 | 88.1 |
|
| 45 | 199 | 84.3 |
|
| 44 | 195 | 82.6 |
|
| 42 | 188 | 79.6 |
|
| 42 | 187 | 79.2 |
|
| 42 | 182.5 | 77.3 |
|
| 41 | 182.5 | 77.3 |
|
| 39 | 175.5 | 74.3 |
|
| 40 | 173 | 73.3 |
|
| 38 | 167 | 70.7 |
|
| 36 | 160.5 | 68 |
|
| 35 | 157.5 | 66.7 |
|
| 36 | 154 | 65.2 |
|
| 33 | 149.5 | 63.3 |
|
| 28 | 128 | 54.2 |
|
| 29 | 124.5 | 52.7 |
|
| 28 | 123.5 | 52.3 |
|
| 22 | 100.5 | 42.5 |
Suggested readings for detailed explanation of selected guideline development tasks.*
| Task | Handbook |
| Selecting the guideline topic | SIGN, NZGG, CSP, ACHR, UPSTF |
| Determining the guideline scope | WHO |
| Adapting relevant existing guidelines | ACHR |
| Involving consumers (patients, …) | SIGN, NZGG |
| Forming guideline development group | WHO |
| Managing conflict of interests | WHO, ACHR |
| Running guideline development group | SIGN |
| Developing clinical questions | NZGG, UPSTF |
| Systematic search for evidence | NZGG |
| Selecting relevant evidence from the search results | UPSTF |
| Appraising identified research evidence | WHO, NZGG, UPSTF |
| Evidence synthesis and analysis | ASCO |
| Consider ethical issues | ACHR |
| Creating recommendation | SIGN, NZGG, ASCO, UPSTF |
| Guideline implementation strategies | SIGN, NHMRC, ASCO |
| Piloting the developed guideline | RCQHC |
The handbooks developed by NICE and SCIH provide a generally comprehensive guidance for guideline development. In this table we only note additional suggestions for further reading.